At the time, ctDNA testing did not exist, single gene EGFR tissue testing was becoming more prevalent with meaningful genotyping failure rates, erlotinib was still approved for unselected NSCLC post chemotherapy, and for patients with failed (unknown) EGFR status clinically unsuitable for chemotherapy, the only management strategy available was supportive care. Here, EGFR is linked to non-small cell lung carcinoma.